Last Price
24.87
Today's Change
-0.29 (1.15%)
Day's Change
24.26 - 25.62
Trading Volume
819,138
Market Cap
1 Billion
Shares Outstanding
70 Million
Avg Volume
671,762
Avg Price (50 Days)
23.36
Avg Price (200 Days)
16.73
PE Ratio
-8.58
EPS
-2.90
Earnings Announcement
12-Feb-2025
Previous Close
25.16
Open
25.29
Day's Range
24.265 - 25.6197
Year Range
4.22 - 26.31
Trading Volume
830,625
1 Day Change
-1.15%
5 Day Change
5.52%
1 Month Change
-2.24%
3 Month Change
9.03%
6 Month Change
69.76%
Ytd Change
143.35%
1 Year Change
287.99%
3 Year Change
-12.55%
5 Year Change
30.83%
10 Year Change
30.83%
Max Change
30.83%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.